Archive: CML Publications
2026 Clinical Papers
February
Development of a prognostic scoring system for chronic myeloid leukemia in blast phase
Lauseker M et al. Leukemia, February 2026 (epub ahead of print)
open access publication
A plain language summary of how the body processes a lower-dose nilotinib tablet (DanzitenTM) compared with the existing capsule (Tasigna®)
Mauro M et al. Future Oncol, February 2026
Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real-life Italian multicenter study
Iurlo A et al. Cancer, February 2026
open access publication
Extended long-term follow-up and the survival of Stop Imatinib Study
Mahon FX et al. Blood Neoplasia, February 2026
open access publication
Leveraging model-informed drug development to predict asciminib efficacy in second-line treatment of chronic myeloid leukemia in chronic phase
Sy SKB et al. Clin Pharmacokinet, February 2026 (epub ahead of print)
Pregnancy-related adverse events with tyrosine kinase inhibitor use in chronic myeloid leukemia: A FAERS Pharmacovigilance analysis (2001 – 2024)
Faisal MS et al. Clin Lymphoma Myeloma Leuk, February 2026
Efficacy and safety of 50 mg versus 100 mg daily frontline dasatinib therapy in chronic-phase chronic myeloid leukemia: a non-controlled, observational dose-comparable cohort study
Cheng F et al. BMC Cancer, February 2026 (epub ahead of print)
open access publication
Second- and third-generation BCR-ABL tyrosine kinase inhibitors and the risk of pulmonary arterial hypertension: A prevalent new-user design
Jambon-Barbara C et al. Circulation, February 2026 (epub ahead of print)
open access publication
A BCR::ABL1 exon 13 variant leads to systematic underestimation of transcript level in the molecular monitoring of CML
Boucher L et al. Leuk Res, February 2026 (epub ahead of print)
Evolving therapeutic algorithms in chronic myeloid leukemia: Integrating efficacy, safety, and survivorship
Leyfman Y et al. Biomedicines, February 2025
open access publication
The importance of bone marrow biopsy for chronic myeloid leukemia classification – a case report
Gonçalves NY et al. HJ Hematop, February 2026
open access publication
Should you be afraid of the big bad wolf? A practical real-world review for the comfortable use of bosutinib in the therapy of chronic myeloid leukemia
Lipton JH. J Cancer Immunol, December 2025
open access publication
Secondary chronic myeloid leukemia in the blast phase with mixed phenotype after radiation therapy: A Case Report
Aoki M et al. EJHaem, February 2026
open access publication
January
Randomized phase 3 trial of Ropeginterferon alpha-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX)
Burchert A et al. Leukemia, January 2026 (epub ahead of print)
open access publication
Risk factors and reasons for switching from front-line therapy in the Italian CML network: A cohort study
Breccia M et al. Br J Haematol, January 2026 (epub ahead of print)
Treatment-free remission after two nilotinib consolidation durations in chronic myeloid leukemia treated with imatinib: Phase 3 ENESTPath results
Réa D et al. Leukemia, January 2026 (epub ahead of print)
Management of chronic myeloid leukemia during pregnancy: Review of evidence and treatment algorithm
Haddad FG et al. Clin Lymphoma Myeloma Leuk, January 2026
Real-world outcomes with low-dose dasatinib (50 mg) in imatinib-resistant chronic myeloid leukemia chronic-phase: A retrospective analysis of efficacy and safety
Gangadaran N et al. Cancer Rep (Hobokken), January 2026
open access publication
Evaluating the safety of combining tyrosine kinase inhibitors with anticoagulants in chronic myeloid leukemia: A systematic review
Gameil A et al. Oncology, January 2026 (epub ahead of print)
open access publication
One-year consolidation with ponatinib 15 mg in chronic myeloid leukemia on deep molecular response with imatinib
Pérez-Lamas L et al. Ann Hematol, January 2026
open access publication
Prediction of relapse after discontinuation of tyrosine kinase inhibitor treatment in chronic myeloid leukemia
Ross DM. Leuk Lymphoma, January 2026 (epub ahead of print)
Introduction to a How I Treat series on chronic myeloid leukemia
Gotlib J. Blood January 2026
How I treat advanced phases of CML
Mauro MJ. Blood, January 2026
How I evaluate and treat resistance and relapse in CML
Soverini S and Castagnetti F. Blood, January 2026
How I individualize frontline treatment for chronic phase CML
Leyte-Vidal A and Shah NP. Blood, January 2026
How I approach hematopoietic stem cell transplantation for CML in a TKI world
Chalandon Y et al. Blood, January 2026
How I manage chronic myeloid leukemia during pregnancy
Abruzzese E, Chelysheva E. Blood January 2026
Advances of next-generation STAMP inhibitors in chronic myeloid leukemia
Costa A and Breccia M. Expert Opin Investig Drugs, January 2026
Drug resistance in chronic myeloid leukemia: The involvement of Galectin-1 and Galectin-3
Yildirim C. Mol Biol Rep, January 2026
Sequential BCR::ABL1 evaluation during dose de-escalation in peripheral blood is more predictive of TFR success than single assessment at dose de-escalation in either peripheral blood or bone marrow
Patterson SD et al. Leukemia, January 2026 (epub ahead of print)
open access publication
An overview of chronic myeloid leukemia treatment:
From tyrosine kinase inhibitors to novel and emerging therapies
Sekar AJ et al. Eur J Haematol, January 2026 (epub ahead of print)
open access publication
Influence of pharmacokinetics-related polymorphisms on asciminib exposure in patients with Japanese chronic myeloid leukemia
Takahashi N et al. Eur J Clin Pharmacol, January 2026
Specifically targeting the ABL myristoyl pocket: STAMP inhibitors for chronic myeloid leukemia
Ureshino H and Kimura S. Expert Rev Hematol, January 2026 (epub ahead of print)
2026 Scientific Papers
February
Intrinsic cellular resistance to BCR::ABL1 inhibitors
Cruz-Rodriguez N et al. Haematologica, February 2026 (epub ahead of print)
open access publication
ERK-mTOR crosstalk suppresses autophagy and upregulates proteasomal degradation pathway to confer chronic myeloid leukemia cells resistant to imatinib
Roy R et al. Exp Hematol, February 2026
High miR-202-5p expression at initial diagnosis is associated with tyrosine kinase inhibitor resistance in chronic myeloid leukemia – a result from a nested Case-Control Study
Nie ZY et al. EJHaem, February 2026
open access publication
Deep cytomorphology identifies erythroid skewing and monocytic morphology to predict TKI sensitivity in CML patients
Luukkainen K et al. Hemasphere, February 2026
open access publication
Peripheral blood neutrophil maturation as a predictor of treatment-free remission in CML
Fujita M et al. Int J Lab Hematol, February 2026 (epub ahead of print)
Potential utility of PPARγ agonists in targeting chronic myeloid leukemia stem cells
Atef B et al. Ann Hematol, February 2026
open access publication
Molecular background of Philadelphia chromosome dependent enhancement of cellular growth and tyrosine kinase inhibitor sensitivity
Hossain MF et al. Exp Hematol Oncol, February 2026
open access publication
ATTEC-mediated degradation of BCR-ABL in chronic myeloid leukemia cells
Wang Z et al. Eur J Med Chem, February 2026
Integrative multi-omics analysis of long non-coding RNA regulatory networks in chronic myeloid leukemia resistance and leukemic stem cell persistence
Soltani I et al. Comput Biol Chem, February 2026
Asciminib and pulsed ATRA as post-remission therapy in T3151I mutated PML_RARA-positive blast crisis of chronic myeloid leukemia
Mazzarella R et al. Ann Hematol, February 2026
open access publication
Quantitative reverse transcription PCR compared with high-resolution melting for simultaneous detection and quantification of four isoforms of BCR::ABL1
Zhou T et al. J Clin Pathol, February 2026
Dual proteasome and histone deacetylase inhibition overcomes tyrosine kinase inhibitor resistance in breakpoint cluster region: Abdelson 1-driven leukaemia cell lines
Okabe S et al. J Cell Mol Med, February 2026
open access publication
January
Hsp-70 Bim interaction mediated mitophagy as a potential therapeutic target for CML stem cells
Song T et al. Stem Cell Reports, January 2026
open access publication
Enhanced detection of splice-altering variants in hematologic malignancies using targeted RNA-sequencing data
Maqsood M et al. J Mol Diagn, January 2026
Identification of a Mushashi2 translocation as a novel oncogene in myeloid leukemia
Spinler K et al. Elife, January 2026
open access publication
Quantitative reverse transcription PCR completed with high-resolution melting for simultaneous detection and quantification of four isoforms of BCR::ABL1
Zhou T et al. J Clin Pathol, January 2026 (epub ahead of print)
Sequential BCR::ABL1 evaluation during dose de-escalation in peripheral blood is more predictive of TFR success than single assessment at dose de-escalation in either peripheral blood or bone marrow
Patterson SD et al. Blood, January 2026 (epub ahead of print)
open access publication
Mmrn1 expression defines a novel subset of hematopoietic stem cells and leukemia stem cells with great self-renewal potential
Chen N et al. Haematologica, January 2026 (epub ahead of print)
open access publication
2026 Low- and Middle-Income Countries Publications
Worldwide Publications of Interest
Next-generation sequencing from chronic myeloid leukemia dried blood spots: Insights and implications for global oncology
Oehler VG et al. Leukemia, January 2026 (epub ahead of print)
CML Publications from Africa
Long-term survival and successful pregnancy in a Nigerian women with concurrent diagnosis of non-Hodgkin lymphoma and chronic myeloid leukemia:
a care report
Ahmed IO et al. J Med Case Rep, January 2026
open access publication
CML Publications from the Middle East
CML Publications from Asia
Clinical significance of the S348I mutation in BCR-ABL as a dominant variant in Indonesian CML patients under tyrosine kinase inhibitor therapy: A Cohort Study
Harjianti T et al. Asian Pac J Cancer Prev, February 2026
open access publication
Impact of bone marrow fibrosis on the outcomes of chronic myeloid leukemia treated with second generation tyrosine kinase inhibitors
Fayyaz F et al. Indian J Hematol Blood Transfus, January 2026
CML Publications from Latin America
2026 Pediatric CML Publications
How I treat chronic myeloid leukemia in children and adolescents
(Chen J et al. Blood, January 2026)
Predictors of response to imatinib therapy and long-term outcomes in pediatric and adolescent patients with CML
(Saha S et al. Cancer Rep Hoboken, January 2026)
Safety profiles of dasatinib in pediatric patients: a real-world pharmacovigilance assessment based on the FAERS database
(Yang Y et al. Jpn J Clin Oncol, January 2026)